coronavirus
compris
larg
famili
rna
virus
infect
wide
varieti
mammalian
avian
host
caus
broad
spectrum
diseas
coronavirus
singlestrand
positivesens
rna
genom
classifi
four
genera
alpha
beta
gamma
deltacoronavirus
coronavirus
prone
mutat
recombin
replic
propens
contribut
exist
divers
coronavirus
sudden
emerg
new
coronavirus
transmit
anim
host
sever
acut
respiratori
syndrom
coronaviru
sarscov
recent
middl
east
respiratori
syndrom
coronaviru
merscov
rais
awar
potenti
risk
highli
virul
coronaviru
infect
human
increas
close
contact
human
anim
harbor
coronavirus
howev
effect
therapeut
measur
coronaviru
infect
elus
far
despit
extens
effort
develop
anticoronaviru
agent
shift
tissu
cell
tropism
result
chang
virul
also
report
coronavirus
porcin
respiratori
coronaviru
caus
mild
respiratori
infect
pig
presum
aros
transmiss
gastroenter
viru
tgev
etiolog
agent
gastroenter
young
pig
high
fatal
spontan
mutat
andor
delet
genom
seemingli
innocu
coronaviru
infect
also
turn
deadli
chang
tropism
exemplifi
mutat
felin
enter
coronaviru
fecv
felin
infecti
periton
viru
fipv
felin
infecti
periton
fip
intrigu
research
half
centuri
sinc
first
descript
infect
fecv
caus
inappar
mild
enter
widespread
among
cat
especi
highdens
environ
littl
clinic
consequ
howev
small
portion
cat
develop
fip
cours
fecv
infect
succumb
diseas
publish
studi
support
fip
aris
individu
cat
mutat
viru
gain
tropism
macrophag
immun
system
infect
cat
play
import
role
pathogenesi
fip
fip
occur
two
major
form
effus
wet
form
noneffus
dri
form
wet
form
common
fip
case
character
accumul
fluid
abdomin
andor
lesser
degre
chest
caviti
granulomat
vascul
frequent
found
omentum
mesenter
lymph
node
seros
surfac
larg
intestin
result
characterist
exud
rich
protein
inflammatori
cell
bodi
caviti
wet
fip
major
exud
cell
virusinfect
macrophag
high
viru
load
detect
cell
multipl
granulomat
lesion
compos
macrophag
laden
virus
inflammatori
cell
typic
form
variou
tissu
organ
omentum
mesenter
lymph
node
spleen
liver
form
fip
clinic
symptom
fip
reflect
organ
involv
includ
fever
jaundic
bodili
effus
weight
loss
may
also
affect
central
nervou
system
eye
virusinduc
immunopathogenesi
lymphopenia
cat
fip
featur
also
frequent
associ
coronaviru
infect
sar
mer
human
caus
lymphopenia
observ
coronaviru
infect
fulli
elucid
publish
report
support
lymphopenia
relat
indirect
effect
viru
infect
lymphopenia
associ
massiv
apoptosi
uninfect
tcell
promin
featur
experiment
natur
fip
implic
cytokin
secret
virusinfect
macrophag
immun
cell
lymphopenia
preced
onset
clinic
sign
associ
diseas
progress
death
experiment
fip
indic
impair
cellular
immun
respons
associ
lymphocyt
deplet
import
fip
pathogenesi
cat
develop
classic
clinic
sign
fatal
fip
virtual
median
surviv
time
time
diagnosi
death
euthanasia
day
fip
lead
caus
death
among
young
cat
year
age
estim
kill
cat
worldwid
fip
also
affect
endang
exot
cat
zoo
jaguar
cheetah
howev
vaccin
proven
ineffect
treatment
palli
studi
anticoronaviru
drug
mainli
focus
discoveri
antisarscov
agent
effect
treatment
intervent
coronaviru
infect
immunopatholog
compon
sar
mer
fip
specul
involv
judici
use
immunomodulatori
agent
enhanc
protect
host
immun
decreas
patholog
immun
respons
antivir
drug
directli
inhibit
viral
replic
previous
report
sever
seri
small
synthet
peptidyl
compound
target
virallyencod
proteas
proteas
coronaviru
papainlik
proteas
plp
process
viral
polyprotein
function
individu
protein
structur
highli
conserv
among
coronavirus
sinc
viral
proteas
indispens
viru
replic
mani
synthet
small
molecul
natur
compound
target
plp
coronavirus
investig
use
vitro
system
howev
studi
test
vivo
efficaci
proteas
inhibitor
experiment
anim
deng
et
report
plp
inhibitor
fail
reduc
viru
titer
lung
increas
surviv
mice
infect
mouseadapt
sarscov
presum
due
low
bioavail
stabil
inhibitor
recent
demonstr
inhibitor
significantli
decreas
viru
titer
patholog
liver
mice
infect
murin
hepat
viru
mhv
murin
coronaviru
studi
treatment
start
shortli
viru
infect
asymptomat
mice
extend
previou
work
coronaviru
inhibitor
investig
pharmacokinet
pk
safeti
efficaci
inhibitor
cat
inhibitor
previous
report
activ
multipl
coronavirus
includ
sarscov
highest
potenc
fipv
cell
cultur
studi
determin
exhibit
favor
bioavail
safeti
cat
vivo
efficaci
studi
use
cat
experiment
infect
fipv
antivir
treatment
start
cat
reach
clinic
stage
would
ultim
lead
death
untreat
antivir
treatment
caus
rapid
revers
clinic
sign
lymphopenia
reduct
viral
titer
macrophag
ascit
activ
infect
longer
appar
day
antivir
treatment
treat
cat
remain
normal
observ
long
eight
month
result
provid
import
first
evid
inhibitor
effect
revers
diseas
progress
administ
cat
advanc
invari
fatal
stage
experiment
induc
fip
fig
repres
compound
dipeptidyl
transit
state
inhibitor
whose
synthesi
describ
previous
share
homolog
structur
element
except
addit
residu
compar
posit
correspond
posit
use
nomenclatur
schechter
berger
fig
compar
antivir
activ
replic
felin
coronaviru
cell
cultur
system
previous
report
fig
howev
pk
properti
report
studi
investig
drug
plasma
concentr
chang
healthi
specif
pathogen
free
spf
cat
month
age
n
compound
follow
singl
subcutan
sc
dose
mgkg
mgkg
serial
blood
sampl
collect
plasma
drug
concentr
measur
previous
report
convert
aldehyd
form
remov
bisulfit
group
aldehyd
form
form
revers
coval
bond
nucleophil
cystein
residu
xray
crystallographi
studi
also
observ
convers
aldehyd
form
blood
therefor
aldehyd
form
measur
plasma
sampl
fig
show
plasma
drug
concentr
time
follow
singledos
administr
red
triangl
black
circl
pk
studi
result
indic
rapidli
absorb
sc
administr
peak
plasma
level
reach
within
hr
inject
mean
plasma
drug
concentr
remain
effect
concentr
valu
aldehyd
form
ngml
hr
post
inject
fig
red
triangl
plasma
drug
concentr
follow
inject
mgkg
stay
valu
aldehyd
form
ngml
hr
post
inject
fig
black
circl
maximum
detect
plasma
drug
concentr
follow
administr
substanti
lower
result
indic
easili
absorb
via
test
rout
even
lower
dose
mgkg
compar
mgkg
taken
account
dosag
regimen
determin
pk
studi
safeti
evalu
four
healthi
spf
cat
month
age
cat
administ
mgkg
sc
inject
twice
daili
pm
week
durat
studi
observ
daili
advers
effect
blood
sampl
taken
weekli
complet
blood
count
blood
chemistri
panel
conduct
studi
period
clinic
signific
chang
vital
sign
clinic
lab
paramet
fig
indic
dosag
rout
administr
welltoler
cat
durat
safeti
studi
safeti
studi
addit
blood
sampl
taken
hr
post
drug
administr
first
three
day
weekli
week
plasma
drug
concentr
hr
post
administr
determin
blood
collect
immedi
next
drug
administr
thu
repres
minimum
drug
level
plasma
result
show
lowest
plasma
drug
concentr
remain
valu
fig
black
triangl
highest
determin
drug
concentr
well
valu
greater
cell
cultur
fig
red
triangl
base
result
safeti
pk
studi
dose
administr
rout
determin
suitabl
vivo
efficaci
studi
experiment
infect
cat
serotyp
fipv
induc
wet
fip
report
previous
fipv
classifi
serotyp
ii
base
viru
neutral
test
serotyp
fipv
respons
major
naturallyoccur
fip
experiment
infect
absolut
lymphopenia
fever
weight
loss
jaundic
inappar
mild
ascit
appear
within
week
infect
increas
jaundic
ascit
occur
next
week
cat
develop
lymphopenia
clinic
sign
follow
experiment
infect
spontan
recov
succumb
diseas
investig
efficaci
conduct
two
independ
studi
studi
antivir
treatment
start
infect
cat
develop
typic
laboratori
find
absolut
lymphopenia
clinic
symptom
determin
whether
treatment
effect
reduc
sever
symptom
fatal
studi
infect
cat
monitor
daili
fever
bodi
weight
outward
diseas
sign
weekli
lymphocyt
count
first
efficaci
studi
four
spf
cat
month
age
intraperiton
administr
catpassag
serotyp
fipv
follow
infect
develop
lymphopenia
clinic
symptom
includ
inappar
mild
ascit
within
day
post
infect
dpi
tabl
second
studi
ascit
four
spf
cat
month
age
inocul
viru
allow
progress
profound
classic
abdomin
effus
close
resembl
cat
naturallyoccur
fip
frequent
present
clinic
tabl
howev
order
allevi
suffer
latter
four
cat
given
meloxicam
nonsteroid
antiinflammatori
drug
subcutan
fluid
prior
antivir
treatment
support
treatment
discontinu
antivir
drug
treatment
commenc
eight
cat
studi
develop
jaundic
inappar
profound
ascit
absolut
lymphopenia
refer
rang
high
fever
fig
tabl
antivir
treatment
start
also
lost
bodi
weight
preinfect
weight
period
fig
reach
stage
twice
daili
sc
administr
mgkgdose
start
cat
treat
day
except
euthan
day
start
antivir
treatment
base
sever
natur
clinic
sign
fig
six
remain
cat
show
rapid
improv
attitud
resolut
fever
fig
profound
absolut
lymphopenia
observ
cat
prior
antivir
treatment
also
return
normal
next
blood
test
one
week
later
fig
weight
loss
revers
normal
growth
resum
fig
ascit
scrotal
swell
indic
periton
also
gradual
resolv
week
antivir
treatment
cat
receiv
antivir
treatment
day
appear
normal
clinic
observ
laboratori
test
six
recov
cat
studi
remain
healthi
show
sign
relaps
observ
period
month
experi
demonstr
proteas
inhibitor
abl
revers
diseas
progress
treatment
initi
advanc
clinic
stage
fip
sinc
fipv
highli
associ
tissu
reliabl
detect
blood
high
level
cat
fip
assess
efficaci
antivir
drug
reduc
viral
load
pose
difficulti
live
anim
although
measur
viru
titer
exud
macrophag
ascit
allow
determin
effect
antivir
drug
replic
fipv
ascit
rapidli
decreas
antivir
treatment
abl
collect
ascit
recov
cat
howev
determin
viral
load
two
cat
second
studi
prior
antivir
treatment
cat
euthan
day
antivir
treatment
necropsi
cat
sever
pancreat
possibl
complic
meloxicam
treatment
lesion
mild
lesion
typic
fip
found
viru
titer
macrophag
ascit
determin
realtim
quantit
rtpcr
ct
valu
analyz
compar
ct
method
use
refer
gene
result
show
viral
rna
level
macrophag
ascit
decreas
commensur
durat
antivir
treatment
cat
fold
reduct
viral
rna
level
determin
use
delta
delta
ct
method
receiv
dayantivir
treatment
fig
receiv
dayantivir
treatment
fig
compar
pretreat
viral
rna
level
macrophag
cat
viral
rna
level
macrophag
ascit
summar
fig
viral
rna
level
omentum
also
shown
fig
base
result
reduct
viru
titer
seem
correl
necropsi
find
mild
fip
lesion
cat
result
viral
titer
show
fipv
valid
target
fipv
antivir
drug
effect
reduc
viru
load
macrophag
ascit
omentum
cat
fip
serial
passag
crandel
ree
felin
kidney
crfk
cell
presenc
aldehyd
form
conduct
compar
emerg
viral
resist
drug
pressur
passag
number
valu
fipv
increas
compar
wildtyp
viru
passag
number
howev
decreas
antivir
activ
fipv
observ
passag
sequenc
analysi
gene
fipv
virus
collect
passag
reveal
singl
mutat
serin
cystein
posit
locat
cii
dii
domain
ii
fig
sinc
compound
share
similar
structur
also
investig
whether
virus
retain
suscept
effect
inhibit
replic
virus
cell
cultur
wildtyp
virus
indic
mutat
confer
crossresist
coronaviru
highli
conserv
structur
activ
site
fig
show
superimpos
structur
merscov
pdb
id
teal
fipv
red
model
base
tgev
pdb
id
tgev
fipv
highli
conserv
amino
acid
sequenc
ident
howev
tgev
merscov
sarscov
low
amino
acid
sequenc
ident
nonetheless
share
well
conserv
overal
structur
fig
activ
previous
report
sarscov
use
fret
assay
howev
activ
merscov
fipv
unknown
therefor
clone
express
fulllength
fipv
merscov
follow
procedur
describ
previous
result
summar
fig
data
show
effect
fipv
fret
assay
also
substanti
inhibit
activ
merscov
sarscov
sinc
fip
diseas
progress
quit
rapid
pathogenesi
fip
primarili
immunemedi
import
question
remain
unansw
whether
antivir
drug
treatment
effect
revers
diseas
progress
symptomat
host
previous
shown
antiinflammatori
agent
antivir
immun
enhanc
agent
increas
surviv
mice
infect
mouseadapt
sarscov
treat
nfkb
inhibitor
variou
tolllik
receptor
agonist
start
shortli
viru
infect
report
indic
control
immun
respons
may
prove
effect
therapeut
strategi
coronaviru
infect
inflamm
play
import
role
pathogenesi
howev
avail
data
efficaci
antivir
compound
fail
show
suffici
effect
mice
infect
mouseadapt
sarscov
even
treatment
start
time
shortli
viru
infect
observ
low
effect
antivir
treatment
larg
thought
due
use
compound
weak
anticoronaviru
activ
andor
bioavail
howev
lack
avail
potent
antivir
compound
coronavirus
made
difficult
investig
effect
antivir
treatment
anim
lethal
coronaviru
infect
inhibitor
previous
report
potent
fipv
vitro
assay
effect
significantli
reduc
viral
titer
tissu
patholog
mice
infect
mhv
howev
inhibitor
test
cat
studi
inhibitor
determin
safe
good
bioavail
cat
vivo
efficaci
studi
use
cat
fip
antivir
treatment
start
cat
clinic
advanc
stage
led
rapid
normal
number
lymphocyt
time
fever
jaundic
ascit
also
resolv
granulomat
lesion
typic
found
variou
organ
cat
infect
fipv
found
greatli
reduc
two
cat
euthan
day
antivir
treatment
result
demonstr
continu
viru
replic
import
progress
immunemedi
pathogenesi
fip
control
viru
replic
directlyact
antivir
compound
target
coronaviru
effect
revers
fip
diseas
result
provid
first
evid
best
knowledg
directact
antivir
agent
effect
revers
immunemedi
diseas
progress
caus
coronaviru
infect
even
antivir
treatment
start
clinic
advanc
stage
find
may
import
implic
devis
effect
therapeut
strategi
coronaviru
infect
conserv
activ
site
coronaviru
consid
promis
target
design
broadspectrum
inhibitor
coronaviru
infect
group
other
previous
report
synthesi
inhibitor
antivir
activ
multipl
coronavirus
previous
shown
activ
fipv
cell
cultur
sarscov
fret
assay
studi
compar
activ
fipv
merscov
sarscov
fret
assay
determin
potent
activ
fipv
valu
merscov
sarscov
respect
higher
fipv
fret
assay
result
indic
activ
coronavirus
belong
alphacoronaviru
fipv
multipl
clade
betacoronaviru
merscov
sarscov
despit
low
sequenc
ident
among
fipv
sarscov
merscov
vari
degre
effect
differ
coronavirus
may
reflect
subtl
differ
spatial
structur
fit
compound
activ
site
coronaviru
fig
howev
antivir
activ
replic
human
coronavirus
yet
determin
cell
cultur
anim
model
major
report
proteas
inhibitor
shown
inhibitori
effect
variou
coronavirus
enzym
assay
tripeptidyl
bulkier
compound
antivir
activ
cell
cultur
vivo
properti
often
avail
studi
compar
subcutan
absorpt
dipeptidyl
tripeptidyl
inhibitor
dipeptidyl
compound
consist
warhead
gln
surrog
structur
posit
correspond
posit
leu
posit
cap
structur
fig
tripeptidyl
compound
homolog
structur
element
except
addit
residu
fig
two
compound
compar
antivir
activ
fipv
cell
cultur
fig
howev
peak
plasma
concentr
follow
subcutan
inject
consider
lower
indic
absorb
better
via
subcutan
rout
result
close
relat
compound
indic
rel
small
structur
chang
addit
residu
profound
effect
absorpt
therefor
bioavail
compound
need
taken
consider
earli
drug
select
process
also
found
welltoler
cat
durat
twice
daili
administr
plasma
drug
concentr
remain
valu
well
valu
emerg
viral
resist
major
concern
antivir
therapi
avail
literatur
proteas
inhibitorresist
coronaviru
report
inhibitor
low
genet
barrier
mhv
studi
resist
virus
select
passag
number
presenc
inhibitor
cell
cultur
resist
virus
highli
attenu
mice
studi
develop
viral
resist
inhibitor
serial
passag
fipv
presenc
mock
vehicl
aldehyd
form
passag
valu
increas
compar
wildtyp
virus
passag
without
indic
emerg
virus
gene
viru
singl
mutat
locat
cii
dii
strand
domain
ii
fig
role
mutat
confer
resist
current
clear
howev
fact
serin
posit
conserv
among
felin
coronavirus
whose
sequenc
avail
activ
site
residu
form
coval
bond
warhead
inhibitor
loop
cii
dii
strand
fig
suggest
mutat
may
influenc
conform
loop
posit
activesit
residu
proteolysi
interestingli
deng
et
al
also
report
one
mutat
mhv
partial
resist
locat
away
catalyt
site
posit
may
influenc
conform
catalyt
site
contrast
resist
virus
select
passag
result
indic
similarli
structur
compound
may
differ
level
resist
barrier
coronaviru
interestingli
virus
lose
suscept
cell
cultur
indic
mutat
confer
crossresist
mechan
underli
differ
resist
develop
inhibitor
need
defin
may
specul
small
size
compar
make
difficult
viru
evad
drug
bind
retain
substrat
cleavag
capabl
current
investig
rel
viral
fit
resist
virus
role
mutat
confer
resist
summari
repres
compound
dipeptidyl
inhibitor
seri
shown
safe
dosag
regimen
use
cat
effect
revers
progress
fip
even
treatment
start
advanc
clinic
stage
base
result
compound
may
potenti
develop
safe
effect
drug
fip
furthermor
broad
activ
compound
import
human
coronavirus
includ
merscov
sarscov
suggest
inhibitor
seri
may
serv
platform
optim
import
virus
result
studi
also
suggest
similar
intervent
approach
target
virallyencod
warrant
investig
exist
emerg
coronaviru
infect
random
bred
cat
free
common
felin
pathogen
includ
felin
enter
coronaviru
obtain
felin
nutrit
breed
coloni
school
veterinari
medicin
uc
davi
anim
experi
conduct
strict
complianc
anim
welfar
act
ph
polici
feder
statut
regul
relat
anim
approv
institut
anim
care
use
committe
univers
california
davi
protocol
synthes
previous
describ
group
singledos
pk
studi
two
healthi
spf
cat
month
age
n
compound
subcutan
inject
mgkg
mgkg
dissolv
etoh
blood
sampl
collect
cat
hr
follow
inject
plasma
sampl
prepar
plasma
drug
concentr
measur
use
routin
high
pressur
liquid
chromatographi
frontag
laboratori
inc
exton
pa
safeti
multipledos
studi
four
healthi
spf
cat
month
age
inject
sc
daili
dose
mgkgdose
dissolv
etoh
pb
pm
week
plasma
sampl
prepar
determin
drug
concentr
hr
immedi
next
dose
drug
administr
first
three
day
weekli
thereaft
week
measur
plasma
drug
concentr
safeti
studi
also
perform
frontag
laboratori
inc
safeti
studi
cat
monitor
twice
daili
advers
effect
bodi
weight
measur
daili
prior
first
dose
thereaft
weekli
blood
sampl
collect
cat
complet
blood
count
blood
chemistri
test
total
eight
femal
male
spf
cat
month
age
two
independ
conduct
studi
origin
part
anoth
publish
experi
concern
role
genet
susceptibilityresist
fipv
infect
studi
cat
inocul
catpassag
serotyp
field
strain
among
cat
develop
clinic
laboratori
sign
consist
abdomin
effus
wet
form
fip
progress
point
would
inevit
fatal
eight
cat
transfer
drug
efficaci
studi
four
cat
first
studi
receiv
medic
five
dose
oral
subcutan
meloxicam
mgkgdose
day
well
fluid
given
four
cat
second
studi
allevi
pain
dehydr
discontinu
antivir
treatment
start
dissolv
etoh
pb
given
sc
pm
day
given
mgkgdose
day
respect
dose
increas
mgkgdose
end
antivir
treatment
euthan
follow
antivir
treatment
day
respect
cat
receiv
mgkgdose
antivir
treatment
anim
observ
daili
clinic
sign
bodi
weight
blood
collect
weekli
lymphocyt
count
ascit
collect
multipl
time
antivir
treatment
viru
titrat
realtim
quantit
rtpcr
qrtpcr
omentum
sampl
collect
necropsi
viru
titer
macrophag
ascit
omentum
determin
realtim
qrtpcr
ascit
ml
collect
dilut
pb
contain
unitsml
heparin
centrifug
cell
pellet
incub
rnalat
life
technolog
ny
usa
overnight
cell
pellet
collect
centrifug
store
analysi
prior
total
rna
extract
pb
ad
cell
pellet
omentum
cut
size
less
cm
place
volum
rnalat
follow
overnight
incub
sampl
centrifug
min
rpm
remov
supernat
tissu
store
analysi
total
rna
extract
macrophag
ascit
omentum
use
rneasi
mini
kit
life
technolog
realtim
qrtpcr
conduct
primer
probe
target
utr
region
fipv
forward
primer
gatccagacgttagct
revers
primer
famagatccgctatgacgagccaacaaiowa
black
probe
rel
level
viral
rna
sampl
calcul
compar
ct
method
use
beta
actin
refer
gene
fold
chang
viral
rna
level
macrophag
ascit
collect
antivir
treatment
calcul
use
viral
rna
level
macrophag
sampl
collect
prior
antivir
treatment
sequenti
vitro
passag
experi
use
wildtyp
presenc
perform
select
resist
virus
briefli
crfk
cell
infect
fipv
moi
presenc
rang
passag
supernat
contain
virus
pass
fresh
cell
presenc
control
mock
viru
passag
absenc
drug
follow
procedur
viru
titer
certain
passag
number
determin
tissu
cultur
infect
dose
assay
fold
chang
valu
rel
wildtyp
viru
determin
passag
presenc
absenc
total
viral
rna
isol
use
rneasi
mini
kit
invitrogen
gene
sequenc
follow
amplif
rtpcr
analyz
presenc
mutat
virus
grown
without
drug
mock
virus
passag
number
purifi
three
time
limit
dilut
investig
virus
suscept
serial
dilut
ad
confluent
monolay
crfk
cell
plate
cell
mocktreat
cell
immedi
infect
viru
moi
follow
incub
extens
cytopath
effect
observ
mocktreat
well
hr
cell
freezethaw
viru
titrat
valu
determin
use
graphpad
prism
softwar
version
graphpad
softwar
san
diego
ca
follow
procedur
describ
previous
codonoptim
cdna
encod
full
length
amplifi
rtpcr
use
omentum
tissu
cat
infect
sarscov
genbank
merscov
genbank
synthes
genscript
piscataway
nj
express
purif
conduct
follow
standard
method
describ
previous
group
primer
mer
forward
primer
attctagaaaggagatataccatgcat
catcatcatcatcatagcggtctggttaaaatgagcc
revers
primer
atctcgagtcactgcatcacaacacccataatc
primer
fipv
forward
primer
attctagaaaggagatataccatgcatcatcatcatcatcattctg
gattgcgaaaaatggc
revers
primer
atctcgaggcggccgctcactgact
fret
assay
perform
use
fluorogen
substrat
dabcylktsavlqsgfrkmeedan
deriv
cleavag
site
viral
polyprotein
sarscov
synthes
genscript
method
fret
assay
describ
previous
group
briefli
fret
assay
fipv
merscov
sarscov
incub
min
edansdabcyl
fret
substrat
deriv
cleavag
site
sarscov
polyprotein
ad
mixtur
follow
incub
min
floresc
signal
measur
calcul
structur
model
fipv
built
base
tgev
pdb
id
use
easymodel
program
version
superimpos
structur
merscov
pdb
id
teal
surfac
represent
activ
site
tgev
pdb
id
merscov
pdb
id
creat
pymol
delano
scientif
